Orega Biotech Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
2ndary - Private
- Investors
-
2
Orega Biotech General Information
Description
Developer of monoclonal antibodies designed to transform scientific insights in the field of tumor immunology into improved responses to cancer immunotherapies. The company's antibodies deal with therapeutic strategies for cancer, focus on the tumor microenvironment and also develop antibodies for modulating regulatory cell activities in cancers, enabling researchers to facilitate improved anticancer strategies, response rates, and patient survival.
Contact Information
Website
www.orega-biotech.comCorporate Office
- Espace Européen, Bâtiment G
- 15 Chemin Du Saquin
- 69130 Ecully
- France
Corporate Office
- Espace Européen, Bâtiment G
- 15 Chemin Du Saquin
- 69130 Ecully
- France
Orega Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | 01-Dec-2022 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC | 13-May-2014 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC | 01-Sep-2010 | $3.7M | $3.7M | Completed | Startup | |
| 1. Accelerator/Incubator | 01-Mar-2010 | Completed | Startup |
Orega Biotech Patents
Orega Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4110810-A1 | Combination therapies based on ctla4 and il-17b inhibitors | Pending | 28-Feb-2020 | ||
| US-20230045494-A1 | Combination therapies based on ctla4 and il-17b inhibitors | Pending | 28-Feb-2020 | ||
| WO-2021170750-A1 | Combination therapies based on ctla4 and il-17b inhibitors | Inactive | 28-Feb-2020 | ||
| EP-4007775-A1 | Novel il-17b antibodies | Pending | 02-Aug-2019 | ||
| US-20220281967-A1 | Novel il-17b antibodies | Inactive | 02-Aug-2019 | C07K16/244 |
Orega Biotech Signals
Orega Biotech Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Turenne Groupe | PE/Buyout | Minority | ||
| UI Investissement | PE/Buyout | Minority |
Orega Biotech FAQs
-
When was Orega Biotech founded?
Orega Biotech was founded in 2010.
-
Where is Orega Biotech headquartered?
Orega Biotech is headquartered in Ecully, France.
-
What is the size of Orega Biotech?
Orega Biotech has 7 total employees.
-
What industry is Orega Biotech in?
Orega Biotech’s primary industry is Drug Discovery.
-
Is Orega Biotech a private or public company?
Orega Biotech is a Private company.
-
What is Orega Biotech’s current revenue?
The current revenue for Orega Biotech is .
-
How much funding has Orega Biotech raised over time?
Orega Biotech has raised $5.08M.
-
Who are Orega Biotech’s investors?
Turenne Groupe and UI Investissement have invested in Orega Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process